Helix Biopharma (OTCMKTS:HBPCF – Get Free Report) and X4 Pharmaceuticals (NASDAQ:XFOR – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability and earnings.
Risk & Volatility
Helix Biopharma has a beta of 0.17, suggesting that its stock price is 83% less volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.34, suggesting that its stock price is 66% less volatile than the S&P 500.
Valuation and Earnings
This table compares Helix Biopharma and X4 Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Helix Biopharma | N/A | N/A | -$3.73 million | ($0.04) | -42.75 |
| X4 Pharmaceuticals | $35.11 million | 10.72 | -$79.20 million | ($4.54) | -0.88 |
Helix Biopharma has higher earnings, but lower revenue than X4 Pharmaceuticals. Helix Biopharma is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Helix Biopharma and X4 Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Helix Biopharma | N/A | -21.61% | -17.14% |
| X4 Pharmaceuticals | -1,106.30% | -94.90% | -48.09% |
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Helix Biopharma and X4 Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Helix Biopharma | 0 | 0 | 0 | 0 | 0.00 |
| X4 Pharmaceuticals | 1 | 1 | 4 | 0 | 2.50 |
X4 Pharmaceuticals has a consensus price target of $9.38, suggesting a potential upside of 134.96%. Given X4 Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe X4 Pharmaceuticals is more favorable than Helix Biopharma.
Insider & Institutional Ownership
72.0% of X4 Pharmaceuticals shares are held by institutional investors. 7.6% of Helix Biopharma shares are held by company insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
X4 Pharmaceuticals beats Helix Biopharma on 7 of the 13 factors compared between the two stocks.
About Helix Biopharma
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.
About X4 Pharmaceuticals
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.
Receive News & Ratings for Helix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
